Anticoagulants Market
Anticoagulants Market Analysis By Drug Class (Factor X Inhibitor (NOAC/DOAC) Anticoagulants, Heparin Anticoagulants, Direct Thrombin Inhibitor Anticoagulants, Vitamin K Antagonist Anticoagulants), By Route of Administration, By Indication - Global Market Insights 2021 to 2031
Analysis of Anticoagulants market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Anticoagulants Market Outlook (2021 to 2031)
The sales of anticoagulant are expected to reach US$ 30 Billion by the end of 2021. As per the study, demand will continue rising, expanding over 2x to be valued at US$ 65 Billion by the end of the 2021 to 2031 assessment period.
Players are increasingly utilizing internet sales channels to extend their reach while requiring less financial commitment. On the demand side, the rising incidence of heart attacks, owing to patients' unhealthy lifestyle choices, is expected to expand the patient pool for the anticoagulants market over the forecast period.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Anticoagulants Consumption Analysis 2016 to 2020 Vs Outlook 2021 to 2031
Sales of anticoagulants expanded at a CAGR of 5% across the historical period ranging from 2016 to 2020. Demand for anticoagulants has increased significantly in emerging nations, owing to the financial assistance provided by central governments to renovate healthcare facilities and improve service quality.
Leading firms are utilizing research and development operations to increase the number of pipeline medicines, recognizing the anticoagulants market's strong growth possibilities. The Global Anticoagulants Market is estimated to be worth US$ 65 Billion by 2031, expanding at an 8.04 % CAGR during the forecast period.
Surging Atrial Fibrillation Cases Spurring Anticoagulants Consumption?
The most common heart arrhythmia is atrial fibrillation. It is projected that 6-12 million individuals in the United States will have this disease by 2050, and 17.9 million people in Europe will have it by 2060. Atrial fibrillation is a substantial risk factor for ischemic stroke, causing a large economic burden as well as morbidity and death.
As per the National Center for Biotechnology Information, during 2017, over 3 million new instances of atrial fibrillation were detected globally. The 2017 estimated incidence rate (403/million inhabitants) was 31% higher than the 1997 corresponding incidence. The global prevalence of atrial fibrillation is 37,574 million instances, and it has grown by 33% in the past two decades.
The biggest burden is observed in nations with a high socio-demographic index; however the most recent growth occurred in countries with a moderate socio-demographic index. According to estimates, the absolute burden of atrial fibrillation may grow by more than 60% by 2050. Hence, all these factors contribute to the market growth during the forecast period.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country Wise Analysis
How do Anticoagulants Growth Prospects Appear in the U.S?
U.S. accounted for the biggest proportion of anticoagulants in 2020, owing to increased knowledge about the therapeutic uses of anticoagulants in disease management and the country's rising obesity prevalence. Furthermore, it has the highest obesity prevalence in the world.
According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence in the United States was 42.4% in 2017 to 2018. Obesity in the United States rose from 30.5% to 42.4% between 1999 and 2018. Based on aforementioned trends, the U.S market is expected to surge at a CAGR of 7.5% until 2031.
How big is the Anticoagulants Industry in Japan?
According to the World Bank, a projected 28% of Japan's total population is over 65 in 2020, with that figure predicted to increase to 40% by 2060. As a result, blood thinners such as Xarelto are widely recommended to the elderly for the treatment and prevention of blood clots. A market share worth 45% is expected for the Japanese market.
With an ageing population, demand for anticoagulants is strong, as they require surgical interventions for numerous chronic conditions. Geriatrics are more likely to have diseases such as venous thromboembolism, atrial fibrillation, and knee and hip replacement operations, increasing their risk of forming blood clots and, as a result, heart attacks and strokes.
Why is China an Emerging Market for Anticoagulants?
China is anticipated to expand at the highest rate throughout the projection period, clocking a CAGR exceeding 8% until 2031. High prevalence rate of cardiovascular diseases is spurring surgeries across the East Asian giant, paving way for high usage of anticoagulants.
According to the Lancet, nearly 4 million deaths occur due to CVDs in China annually. In an effort to mitigate the risk and reduce this burden, healthcare practitioners are advocating advanced surgical interventions. However, the risk of embolism arising from such surgeries has also increased, prompting usage of anticoagulants.
Category Wise Insights
Why the Preference for NOAC/DOAC Factor X Inhibitors?
By drug class, NOAC/DOAC factor X inhibitors accounted for over 50% of total anticoagulants demand in 2019. This is attributed to increased NOAC uptake in poorer nations, as well as increased usage of NOACs over warfarin.
Furthermore, NOACs including betrixaban, rivaroxaban, apixaban, dabigatran, and edoxaban are used to treat and prevent atrial fibrillation/myocardial infarction, pulmonary embolism, and deep vein thrombosis (DVT). They possess numerous advantages over warfarin, including minimal dietary restrictions, fast start effect, predictable pharmacokinetic action, less drug and food interaction, and a shorter half-life.
Why are Hospital Pharmacies Primary Anticoagulants Distributors?
Hospital pharmacies are expected to account for 49.2% revenue share. This is because hospitals are the major sites for the diagnosis and treatment of many forms of bleeding problems.
As the volume of surgeries for various chronic conditions increase, episodes of embolisms post-surgery are increasing manifold. As a result, doctors highly recommend use of anticoagulants to prevent further complications in the patient.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
The anticoagulants landscape is competitive and fragmented, with numerous significant competitors. As a tool to increase anticoagulant exposure, players in the anticoagulants industry are stepping forward to carry the financial burden of individuals through patient-assistance programmes.
- In August 2020, Bristol-Myers Squibb, in alliance with Pfizer, announced that the U.S District Court upheld their composition of matter (COP) patent (US 6,967,208) and formulation patent (US 9,326,945) covering their Eliquis® Apixaban anticoagulants.
- Likewise, in November 2020, Boehringer Ingelheim received approval from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) for the use of Pradaxa® (dabigatran etexilate) for treating venous thromboembolic events and preventing its recurrence in pediatric patients below 18 years
Report Scope
| Report Attributes | Details |
|---|---|
| The market size value in 2021 | USD 30 Billion |
| Market forecast value in 2031 | USD 65 Billion |
| Growth Rate | CAGR of 8.04% from 2021 to 2031 |
| Forecast Period | 2021 to 2031 |
| Historical Data Available for | 2016 to 2020 |
| Key Market Segments Covered | Drug Class , Indication, Route of Administration, Distribution Channel, Region |
| Key Companies Profiled | Bayer AG; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Daiichi Sankyo Company Ltd.; Sanofi SA; Johnson & Johnson |
Key Segments Covered
-
By Drug Class
- Factor X Inhibitor (NOAC/DOAC) Anticoagulants
- Heparin Anticoagulants
- Direct Thrombin Inhibitor Anticoagulants
- Vitamin K Antagonist Anticoagulants
-
By Indication
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation & Heart Attack
- Other Indications
-
By Route of Administration
- Oral Anticoagulants
- Injectable Anticoagulants
-
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Market
- 4. Market Overview
- 5. Market Outlook
- 6. Global Market Analysis and Forecast, by Route of Administration
- 6.1. Oral
- 6.2. Injectable
- 7. Global Market Analysis and Forecast, by Drug Class
- 7.1. Factor XA Inhibitors (NOAC/DOAC)
- 7.2. Heparins
- 7.3. Direct Thrombin Inhibitors
- 7.4. Vitamin K Antagonists
- 8. Global Market Analysis and Forecast, by Indication
- 8.1. Deep Vein Thrombosis
- 8.2. Pulmonary Embolism
- 8.3. Atrial Fibrillation & Heart Attack
- 8.4. Others
- 9. Global Market Analysis and Forecast, by Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Online Pharmacies
- 10. Global Market Analysis and Forecast, by Region
- 10.1. North America
- 10.2. Europe
- 10.3. Asia Pacific
- 10.4. Latin America
- 10.5. Middle East & Africa
- 11. North America Market Analysis and Forecast
- 12. Europe Market Analysis and Forecast
- 13. Asia Pacific Market Analysis and Forecast
- 14. Latin America Market Analysis and Forecast
- 15. Middle East & Africa Market Analysis and Forecast
- 16. Competition Landscape
- 16.1. Bayer AG
- 16.2. Boehringer Ingelheim International GmbH
- 16.3. Bristol-Myers Squibb Company
- 16.4. Daiichi Sankyo Company, Limited
- 16.5. Sanofi
- 16.6. Johnson & Johnson Services
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 02: Global Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 03: Global Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 04: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 05: Global Market Size (US$ Mn) and Volume (Units) Forecast, by Region, 2021 to 2031
Table 06: North America Market Value (US$ Mn) Forecast, by Country, 2016 to 2031
Table 07: North America Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 08: North America Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 09: North America Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 10: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 11: Europe Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 12: Europe Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 13: Europe Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 14: Europe Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 15: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 16: Asia Pacific Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 17: Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 18: Asia Pacific Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 19: Asia Pacific Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 20: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 21: Latin America Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 22: Latin America Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 23: Latin America Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 24: Latin America Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 25: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
Table 26: Middle East & Africa Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016 to 2031
Table 27: Middle East & Africa Market Value (US$ Mn) Forecast, by Route of Administration, 2016 to 2031
Table 28: Middle East & Africa Market Value (US$ Mn) Forecast, by Drug Class, 2016 to 2031
Table 29: Middle East & Africa Market Value (US$ Mn) Forecast, by Indication, 2016 to 2031
Table 30: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 to 2031
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Size Value (US$ Mn) Forecast, 2016 to 2031
Figure 02: Global Market Value Share (%), by Route of Administration, 2021
Figure 03: Global Market Value Share (%), by Drug Class, 2021
Figure 04: Global Market Value Share (%), by End-user, 2021
Figure 05: Global Market Value Share (%), by Region, 2021
Figure 06: Global Market Value Share, by Route of Administration, 2021 and 2031
Figure 07: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oral, 2016 to 2031
Figure 08: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Injectables, 2016 to 2031
Figure 09: Global Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 10: Global Market Value Share, by Drug Class, 2021 and 2031
Figure 11: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Factor XA Inhibitors, 2016 to 2031
Figure 12: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Heparins, 2016 to 2031
Figure 13: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Direct Thrombin Inhibitors, 2016 to 2031
Figure 14: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Vitamin K Antagonists, 2016 to 2031
Figure 15: Global Market Attractiveness, by Drug Class, 2021 to 2031
Figure 16: Global Market Value Share, by Indication, 2021 and 2031
Figure 17: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Deep Vein Thrombosis (DVT), 2016 to 2031
Figure 18: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pulmonary Embolism (PE), 2016 to 2031
Figure 19: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Atrial Fibrillation & Heart Attack, 2016 to 2031
Figure 20: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016 to 2031
Figure 21: Global Market Attractiveness, by Indication, 2021 to 2031
Figure 22: Global Market Value Share, by Distribution Channel, 2021 and 2031
Figure 23: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospitals Pharmacies, 2016 to 2031
Figure 24: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2016 to 2031
Figure 25: Global Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016 to 2031
Figure 26: Global Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 27: Global Market Value Share Analysis, by Region, 2021 and 2031
Figure 28: Global Market Attractiveness Analysis, by Region, 2021 and 2031
Figure 29: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 30: North America Market Value Share, by Country, 2021 and 2031
Figure 31: North America Market Attractiveness, by Country, 2021 to 2031
Figure 32: North America Market Value Share, by Route of Administration, 2021 and 2031
Figure 33: North America Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 34: North America Market Value Share, by Drug Class, 2021 and 2031
Figure 35: North America Market Attractiveness, by Drug Class, 2021 to 2031
Figure 36: North America Market Value Share, by Indication, 2021 and 2031
Figure 37: North America Market Attractiveness, by Indication, 2021 to 2031
Figure 38: North America Market Value Share, by Distribution Channel, 2021 and 2031
Figure 39: North America Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 40: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 41: Europe Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 42: Europe Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 43: Europe Market Value Share, by Route of Administration, 2021 and 2031
Figure 44: Europe Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 45: Europe Market Value Share, by Drug Class, 2021 and 2031
Figure 46: Europe Market Attractiveness, by Drug Class, 2021 to 2031
Figure 47: Europe Market Value Share, by Indication, 2021 and 2031
Figure 48: Europe Market Attractiveness, by Indication, 2021 to 2031
Figure 49: Europe Market Value Share, by Distribution Channel, 2021 and 2031
Figure 50: Europe Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 51: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 52: Asia Pacific Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 53: Asia Pacific Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 54: Asia Pacific Market Value Share, by Route of Administration, 2021 and 2031
Figure 55: Asia Pacific Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 56: Asia Pacific Market Value Share, by Drug Class, 2021 and 2031
Figure 57: Asia Pacific Market Attractiveness, by Drug Class, 2021 to 2031
Figure 58: Asia Pacific Market Value Share, by Indication, 2021 and 2031
Figure 59: Asia Pacific Market Attractiveness, by Indication, 2021 to 2031
Figure 60: Asia Pacific Market Value Share, by Distribution Channel, 2021 and 2031
Figure 61: Asia Pacific Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 62: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 63: Latin America Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 64: Latin America Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 65: Latin America Market Value Share, by Route of Administration, 2021 and 2031
Figure 66: Latin America Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 67: Latin America Market Value Share, by Drug Class, 2021 and 2031
Figure 68: Latin America Market Attractiveness, by Drug Class, 2021 to 2031
Figure 69: Latin America Market Value Share, by Indication, 2021 and 2031
Figure 70: Latin America Market Attractiveness, by Indication, 2021 to 2031
Figure 71: Latin America Market Value Share, by Distribution Channel, 2021 and 2031
Figure 72: Latin America Market Attractiveness, by Distribution Channel, 2021 to 2031
Figure 73: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016 to 2031
Figure 74: Middle East & Africa Market Value Share, by Country/Sub-region, 2021 and 2031
Figure 75: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2021 to 2031
Figure 76: Middle East & Africa Market Value Share, by Route of Administration, 2021 and 2031
Figure 77: Middle East & Africa Market Attractiveness, by Route of Administration, 2021 to 2031
Figure 78: Middle East & Africa Market Value Share, by Drug Class, 2021 and 2031
Figure 79: Middle East & Africa Market Attractiveness, by Drug Class, 2021 to 2031
Figure 80: Middle East & Africa Market Value Share, by Indication, 2021 and 2031
Figure 81: Middle East & Africa Market Attractiveness, by Indication, 2021 to 2031
Figure 82: Middle East & Africa Market Value Share, by Distribution Channel, 2021 and 2031
Figure 83: Middle East & Africa Market Attractiveness, by Distribution Channel, 2021 to 2031
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the global anticoagulants market worth?
According to Fact.MR, the anticoagulants industry is expected to reach US$ 30 Bn in 2021.
What was the last 5 years CAGR for the anticoagulants industry?
From 2016 to 2020, Fact.MR estimated the market for anticoagulants soared at 5% CAGR
What is the anticipated future outlook for the anticoagulants landscape?
From 2021 to 2031, anticoagulants demand is expected to surge at a CAGR exceeding 8%
What is the most prevalent trend driving anticoagulants uptake?
Rising prevalence of atrial fibrillation and heart attacks is anticipated to increase uptake of anticoagulants
What is the U.S market outlook for anticoagulants?
Demand for anticoagulants in the U.S is expected to surge at a CAGR of 7.5% from 2021 to 2031
What is the growth outlook for the market in Japan?
Anticoagulants sales are expected to comprise 45% of the revenue share across Japan
How lucrative are growth prospects in China?
China is anticipated to register a growth rate of over 8% across the forthcoming decade
Which is the most preferred anticoagulant drug class?
NOAC/DOAC factor X-inhibitors are expected to be highly sought after, capturing 50% of total demand
Which is the most preferred distribution channel for anticoagulants?
Hospital pharmacies account for bulk of anticoagulants distribution, yielding 49.2% revenue
Anticoagulants Market